{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:16:53Z","timestamp":1793110613938,"version":"4.5.0"},"reference-count":90,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>The integration of artificial intelligence (AI) and machine learning (ML) in oncology clinical trials is rapidly evolving alongside the broader field. For example, AI-driven adaptive trial designs may allow for real-time modifications based on emerging safety and efficacy signals, enabling more responsive and efficient trials. AI-powered diagnostic tools, including radiomics, computational pathology, and spatial omics, can improve trial patient selection and response assessments. ML-based patient outcome simulations can similarly enhance patient stratification strategies and statistical power. Application of AI can also improve the accessibility of real-world data, including opportunities to enhance data extraction, standardization, and harmonization of data from routine clinical practice. Data generated from digital health technologies (eg, wearable devices, electronic sensors, computing platforms, software applications) may enable a more comprehensive understanding of patient populations to support clinical trials from enrollment to assessment. Automation of trial operations and data management can also improve data fidelity and decrease investigator burden, which has the potential to streamline trial execution and increase potential use of decentralization. There are ongoing efforts to enhance regulatory clarity, mitigate bias, and uphold ethical use of these novel technologies. In this article, we review use cases of AI and ML in oncology clinical trials, including their role in patient recruitment, trial design and operations, data management, and diagnostics. Although these technologies can have applications across all phases of drug development including early discovery, we focus on phase II and III trials, where AI and ML may have a pronounced ability to enhance trial efficiency, patient stratification, and regulatory decision making. By integrating AI and ML, clinical trials can become more adaptive, data-driven, and inclusive in the pursuit of improving patient outcomes.<\/jats:p>","DOI":"10.1200\/edbk-25-473590","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T15:59:13Z","timestamp":1747929553000},"source":"Crossref","is-referenced-by-count":27,"title":["Artificial Intelligence and Machine Learning Innovations to Improve Design and Representativeness in Oncology Clinical Trials"],"prefix":"10.1200","volume":"45","author":[{"given":"Tali","family":"Azenkot","sequence":"first","affiliation":[{"name":"University of California at San Diego Moores Cancer Center, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna R.","family":"Rivera","sequence":"additional","affiliation":[{"name":"Oncology Center of Excellence, US Food and Drug Administration, Silver Springs, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Stewart","sequence":"additional","affiliation":[{"name":"Friends of Cancer Research, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8387-4840","authenticated-orcid":true,"given":"Sandip P.","family":"Patel","sequence":"additional","affiliation":[{"name":"University of California at San Diego Moores Cancer Center, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_3_2_2","volume-title":"FDA Digital Health and Artificial Intelligence Glossary\u2014Educational Resource","unstructured":"FDA Digital Health and Artificial Intelligence Glossary\u2014Educational Resource. https:\/\/www.fda.gov\/science-research\/artificial-intelligence-and-medical-products\/fda-digital-health-and-artificial-intelligence-glossary-educational-resource"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmedinf.2025.105798"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12553-023-00738-2"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05489-x"},{"key":"e_1_3_3_6_2","article-title":"Will artificial intelligence replace doctors?","author":"Budd K","year":"2019","unstructured":"Budd K: Will artificial intelligence replace doctors? AAMCNews, 2019","journal-title":"AAMCNews"},{"key":"e_1_3_3_7_2","volume-title":"A.I. May Someday Work Medical Miracles. For Now, it Helps Do Paperwork 2023","author":"Lohr S","unstructured":"Lohr S: A.I. May Someday Work Medical Miracles. For Now, it Helps Do Paperwork 2023. https:\/\/www.nytimes.com\/2023\/06\/26\/technology\/ai-health-care-documentation.html"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/fi16120462"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53081-z"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-024-01274-7"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e13501"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102304"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0311510"},{"key":"e_1_3_3_14_2","article-title":"Natural language processing for patient selection in phase I or II oncology clinical trials","author":"Delorme J","unstructured":"Delorme J, Charvet V, Wartelle M, et al: Natural language processing for patient selection in phase I or II oncology clinical trials. JCO Clin Cancer Inform 10.1200\/CCI.21.00003","journal-title":"JCO Clin Cancer Inform"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263193"},{"key":"e_1_3_3_16_2","first-page":"205520762412423","article-title":"Digital technologies used in clinical trial recruitment and enrollment including application to trial diversity and inclusion: A systematic review","volume":"10","author":"Kasahara A","year":"2024","unstructured":"Kasahara A, Mitchell J, Yang J, et al: Digital technologies used in clinical trial recruitment and enrollment including application to trial diversity and inclusion: A systematic review. Digit Health 10:20552076241242390, 2024","journal-title":"Digit Health"},{"key":"e_1_3_3_17_2","unstructured":"Grove AI: Meet grace: The industry-leading digital staff for clinical trial operations 2025. https:\/\/www.grovetrials.com\/"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.1838"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115274"},{"key":"e_1_3_3_20_2","article-title":"Machine learning to predict the individual risk of treatment-relevant toxicity for patients with breast cancer undergoing neoadjuvant systemic treatment","author":"Cai L","unstructured":"Cai L, Deutsch TM, Sidey-Gibbons C, et al: Machine learning to predict the individual risk of treatment-relevant toxicity for patients with breast cancer undergoing neoadjuvant systemic treatment. JCO Clin Cancer Inform 10.1200\/CCI.24.00010","journal-title":"JCO Clin Cancer Inform"},{"key":"e_1_3_3_21_2","article-title":"Thirty-day unplanned hospital readmissions in patients with cancer and the impact of social determinants of health: A machine learning approach","author":"Stabellini N","unstructured":"Stabellini N, Nazha A, Agrawal N, et al: Thirty-day unplanned hospital readmissions in patients with cancer and the impact of social determinants of health: A machine learning approach. JCO Clin Cancer Inform 10.1200\/CCI.22.00143","journal-title":"JCO Clin Cancer Inform"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1441"},{"key":"e_1_3_3_23_2","volume-title":"Conducting Clinical Trials with Decentralized Elements 2024","author":"US Department of Health and Human Services","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), et al: Conducting Clinical Trials with Decentralized Elements 2024. https:\/\/www.fda.gov\/media\/167696\/download"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jamiaopen\/ooab107"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03430-5"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jamia\/ocy178"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2024.104649"},{"key":"e_1_3_3_28_2","first-page":"319","article-title":"Real-world application of racial and ethnic imputation and cohort balancing techniques to deliver equitable clinical trial recruitment","volume":"2023","author":"Craig KJ","year":"2023","unstructured":"Craig KJ, Ji YJ, Zhang YC, et al: Real-world application of racial and ethnic imputation and cohort balancing techniques to deliver equitable clinical trial recruitment. AMIA Annu Symp Proc 2023:319-328, 2023","journal-title":"AMIA Annu Symp Proc"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13897"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14111101"},{"key":"e_1_3_3_31_2","first-page":"69","article-title":"Integrating artificial intelligence-driven wearable technology in oncology decision-making: A narrative review","volume":"103","author":"Birla M","year":"2025","unstructured":"Birla M, Rajan, Roy PG, et al: Integrating artificial intelligence-driven wearable technology in oncology decision-making: A narrative review. Oncology 103:69-82, 2025","journal-title":"Oncology"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.2196\/35157"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00358"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390084"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12902"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s41666-020-00077-1"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/CAT.23.0404"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.2024.20.10_suppl.408"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-024-00753-x"},{"key":"e_1_3_3_40_2","volume-title":"The Impact of Doximity GPT on Physician Workflows 2023","author":"Dashevsky J","unstructured":"Dashevsky J: The Impact of Doximity GPT on Physician Workflows 2023. https:\/\/www.healthcarehuddle.com\/p\/impact-doximity-gpt-physician-workflows"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.141"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2021210391"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01345"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thorsurg.2023.03.001"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01337"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0419"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.1564"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e13545"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e13643"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejro.2024.100562"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107507"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00790-9"},{"key":"e_1_3_3_53_2","doi-asserted-by":"crossref","unstructured":"Naidoo J Haakensen VD Bar J et al: Quantitative radiomics for the detection of symptomatic pneumonitis following chemoradiotherapy in patients with stage III unresectable NSCLC 2024. https:\/\/oncologypro.esmo.org\/meeting-resources\/esmo-congress-2024\/quantitative-radiomics-for-the-detection-of-symptomatic-pneumonitis-following-chemoradiotherapy-in-patients-with-stage-iii-unresectable-nsclc","DOI":"10.1016\/j.annonc.2024.08.1298"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-4148"},{"key":"e_1_3_3_55_2","article-title":"Clinical nomogram using novel computed tomography-based radiomics predicts survival in patients with non-small-cell lung cancer treated with stereotactic body radiation therapy","author":"Somasundaram E","unstructured":"Somasundaram E, Wadhwa RR, Litzler A, et al: Clinical nomogram using novel computed tomography-based radiomics predicts survival in patients with non-small-cell lung cancer treated with stereotactic body radiation therapy. JCO Clin Cancer Inform 10.1200\/CCI.22.00173","journal-title":"JCO Clin Cancer Inform"},{"key":"e_1_3_3_56_2","volume-title":"A Friends of Cancer Research White Paper: Supporting the Application of Computational Pathology in Oncology","unstructured":"A Friends of Cancer Research White Paper: Supporting the Application of Computational Pathology in Oncology. https:\/\/friendsofcancerresearch.org\/wp-content\/uploads\/Supporting_the_Application_of_Computational_Pathology_in_Oncology.pdf"},{"key":"e_1_3_3_57_2","unstructured":"McKelvey B Torres-Saavedra PA Li J et al: Agreement across 10 artificial intelligence models in assessing HER2 in breast cancer whole slide images: Findings from the friends of cancer research digital PATH Project 2024. https:\/\/friendsofcancerresearch.org\/wp-content\/uploads\/SABCS-Poster_Digital-PATH-Project-Findings.pdf"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00770-z"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-61957-9"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.015"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-020-0275-x"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2023.02.020"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpi.2023.100308"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05672-3"},{"key":"e_1_3_3_65_2","article-title":"Comparison of imaging-based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed, paraffin-embedded tumor samples","author":"Lermi NO","unstructured":"Lermi NO, Ayala MM, Ruiz SH, et al: Comparison of imaging-based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed, paraffin-embedded tumor samples. bioRxiv 10.1101\/2024.12.13.628390 [epub ahead of print on December 17, 2024]","journal-title":"bioRxiv"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1093\/jamia\/ocad211"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00333-7"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.666937"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.5888\/pcd21.240245"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14122897"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0373"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1007\/s44163-024-00114-7"},{"key":"e_1_3_3_73_2","unstructured":"The World Health Organization: Ethics and governance of artificial intelligence for health: Guidance on large multi-modal models 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240084759"},{"key":"e_1_3_3_74_2","volume-title":"Working Groups 2025","author":"American Medical Informatics Association","unstructured":"American Medical Informatics Association: Working Groups 2025. https:\/\/amia.org\/communities\/working-groups"},{"key":"e_1_3_3_75_2","volume-title":"Chai Assurance Standards Guide 2024","author":"Coalition for Health AI","unstructured":"Coalition for Health AI: Chai Assurance Standards Guide 2024. https:\/\/chai.org\/wp-content\/uploads\/2024\/06\/CHAI_AssuranceGuide_062624.pdf"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-022-00663-0"},{"key":"e_1_3_3_77_2","volume-title":"Principles for the Responsible Use of Artificial Intelligence in Oncology 2024","author":"American Society of Clinical Oncology (ASCO)","unstructured":"American Society of Clinical Oncology (ASCO): Principles for the Responsible Use of Artificial Intelligence in Oncology 2024. https:\/\/www.asco.org\/news-initiatives\/policy-news-analysis\/asco-sets-six-guiding-principles-ai-oncology"},{"key":"e_1_3_3_78_2","volume-title":"Using Artificial Intelligence & Machine Learning in the Development of Drug & Biological Products: Discussion Paper and Request for Feedback 2025","author":"U.S. Food & Drug Administration","unstructured":"U.S. Food & Drug Administration: Using Artificial Intelligence & Machine Learning in the Development of Drug & Biological Products: Discussion Paper and Request for Feedback 2025. https:\/\/www.fda.gov\/media\/167973\/download"},{"key":"e_1_3_3_79_2","unstructured":"Center for Veterinary Medicine Office of Inspections and Investigations Oncology Center of Excellence et al: Considerations for the use of artificial intelligence to support regulatory decision-making for drug and biological products: Draft Guidance for Industry and other interested parties 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological"},{"key":"e_1_3_3_80_2","article-title":"Artificial intelligence-enabled device software functions: Lifecycle management and marketing submission recommendations","author":"Center for Devices and Radiological Health","year":"2025","unstructured":"Center for Devices and Radiological Health, Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research: Artificial intelligence-enabled device software functions: Lifecycle management and marketing submission recommendations. Draft Guidance Industry Food Drug Adm Staff, 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/artificial-intelligence-enabled-device-software-functions-lifecycle-management-and-marketing","journal-title":"Draft Guidance Industry Food Drug Adm Staff"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2668"},{"key":"e_1_3_3_82_2","unstructured":"U.S. Food & Drug Administration: Artificial intelligence and machine learning (AI\/ML)-Enabled medical devices 2024. https:\/\/www.fda.gov\/medical-devices\/software-medical-device-samd\/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices"},{"key":"e_1_3_3_83_2","unstructured":"European Medicines Agency: Multidisciplinary: Artificial intelligence (AI). https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/scientific-guidelines\/multidisciplinary-guidelines\/multidisciplinary-artificial-intelligence-ai?utm_source=chatgpt.com"},{"key":"e_1_3_3_84_2","unstructured":"The Medicines and Healthcare products Regulatory Agency: Guidance: Software and artificial intelligence (AI) as a medical device. https:\/\/www.gov.uk\/government\/publications\/software-and-artificial-intelligence-ai-as-a-medical-device\/software-and-artificial-intelligence-ai-as-a-medical-device?utm_source=chatgpt.com"},{"key":"e_1_3_3_85_2","unstructured":"Research FoC: Considerations for developing reference data sets for digital pathology biomarkers: Friends of cancer research discussion document 2025. https:\/\/friendsofcancerresearch.org\/wp-content\/uploads\/Considerations-for-Developing-Reference-Data-Sets-for-Digital-Pathology-Biomarkers-.pdf"},{"key":"e_1_3_3_86_2","unstructured":"Good machine learning practice for medical device development: Guiding principles. https:\/\/www.fda.gov\/medical-devices\/software-medical-device-samd\/good-machine-learning-practice-medical-device-development-guiding-principles"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.2196\/53008"},{"key":"e_1_3_3_88_2","first-page":"1","article-title":"Artificial intelligence in oncology: Current capabilities, future opportunities, and ethical considerations","volume":"42","author":"Shreve JT","year":"2022","unstructured":"Shreve JT, Khanani SA, Haddad TC: Artificial intelligence in oncology: Current capabilities, future opportunities, and ethical considerations. Am Soc Clin Oncol Educ Book 42:1-10, 2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0068"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.2196\/22214"},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.60637"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-25-473590","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T15:59:25Z","timestamp":1747929565000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-25-473590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":90,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1200\/EDBK-25-473590"],"URL":"https:\/\/doi.org\/10.1200\/edbk-25-473590","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"article-number":"e473590"}}